Advertisement

ADVERTISEMENT

outcomes research

News
First-Line Biosimilar-Based Triplet Effective in HER2-Positive Gastric Cancer
07/08/2020
A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...
A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...
A...
07/08/2020
Journal of Clinical Pathways
News
Cryoablation vs Surgery for Early-Stage Kidney Cancer
07/01/2020
A minimally invasive procedure is as effective as surgery for treating early-stage kidney cancer, according to 10-year survival data published in Radiology (online June 9, 2020;...
A minimally invasive procedure is as effective as surgery for treating early-stage kidney cancer, according to 10-year survival data published in Radiology (online June 9, 2020;...
A...
07/01/2020
Journal of Clinical Pathways
News
Evaluating Neutropenia Prevalence After Venetoclax Therapy for CLL
06/23/2020
A study at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) evaluated fixed duration venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
A study at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) evaluated fixed duration venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
A...
06/23/2020
Journal of Clinical Pathways
News
Isatuximab Combination Effective in Myeloma and Soft-Tissue Plasmacytomas
06/22/2020
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
...
06/22/2020
Journal of Clinical Pathways
News
Refining Selection Criteria for Immune Checkpoint Inhibitors in Recurrent Ovarian Cancer
06/19/2020
Tumor mutation burden (TMB), BRCA1/2 mutations, and homologous DNA repair deficiency (HRD) are not associated with immune checkpoint inhibitor response or survival in recurrent ovarian cancer, according to an...
Tumor mutation burden (TMB), BRCA1/2 mutations, and homologous DNA repair deficiency (HRD) are not associated with immune checkpoint inhibitor response or survival in recurrent ovarian cancer, according to an...
Tumor...
06/19/2020
Journal of Clinical Pathways
News
NCCN Biomarker Guideline Adherence Linked With Decreased Mortality in NSCLC
06/16/2020
Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...
Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...
Adherence to the National...
06/16/2020
Journal of Clinical Pathways
News
PARP Inhibitor vs Nonplatinum Chemo for Platinum-Sensitive, Relapsed Ovarian Cancer
06/09/2020
Olaparib improves survival outcomes for patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer who received at least two prior lines of platinum-based chemotherapy, according to a...
Olaparib improves survival outcomes for patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer who received at least two prior lines of platinum-based chemotherapy, according to a...
...
06/09/2020
Journal of Clinical Pathways
News
Acalabrutinib Significantly Improves Survival in Relapsed, Refractory CLL
06/03/2020
Compared with two rituximab-containing regimens, acalabrutinib significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL) and has a comparable safety profile to these...
Compared with two rituximab-containing regimens, acalabrutinib significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL) and has a comparable safety profile to these...
...
06/03/2020
Journal of Clinical Pathways
News
Survey: Social Determinants of Health Significantly Impact Outcomes for Cancer Patients
06/03/2020
A research-based report series that analyzed the views of more than 160 US oncologists found that social determinants of health are believed to play a significant role in patient outcomes. Findings of the report...
A research-based report series that analyzed the views of more than 160 US oncologists found that social determinants of health are believed to play a significant role in patient outcomes. Findings of the report...
A...
06/03/2020
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 6 ⁠–⁠ November 8
NEI Congress
November 7 ⁠–⁠ November 10
ECS
November 8 ⁠–⁠ November 10
WoundCon
November 8
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use